Brief summary

The Strength study aim to evaluate the use of the RenalGuard device to protect the patients at high risk to develop acute kidney injury following a complex cardiovascular intervention requiring a high volume of contrast.

Primary endpoints

• Occurence of contrast-induced nephropathy [ Time Frame: Within 5 days ]

The occurence of contrast-induced nephropathy will be determined:

by an elevation, within 3 days from requiring contrast-procedure, of the serum creatinine (rise of 0.3mg/dl or of 25% compared to basal value) and/or

by the need for dialysis within 5 fays from requiring contrast-procedure

CERC Services

• Full package: submission, monitoring, CEC, statistics, final report.

Countries

France & Germany managed by CERC.

Centers number

11 centers managed by CERC.